Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Clovis Oncology Inc 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 USA

P: 303-625-5000 F: 303-245-0360

Description:

Clovis Oncology, Inc. is a biopharmaceutical companyfocused on acquiring, developing and commercializing innovative anti-cancer agents.'Clovis has only one marketed drug in its portfolio a poly ADP-ribose polymerase inhibitor, namely Rubraca that is approved for the treatment of certain patients with ovarian and prostate cancer.'Currently, Rubraca is approved in the United States for two indications specific to ovarian cancer in the second and third or later-line setting. The drug is also approved in the United States under accelerated approval as monotherapy for treating BRCA-mutant metastatic castrate-resistant prostate cancer.'A broad development program on Rubraca is currently underway across a variety of solid tumors. Clovis is looking to expand Rubraca's label into additional cancer types like breast and gastroesophageal cancers, among others. Meanwhile, Clovis holds global development and commercialization rights to Rubraca.

Key Statistics

Overview:

Market Capitalization, $K 42,254
Enterprise Value, $K 68,784
Shares Outstanding, K 144,955
Annual Sales, $ 148,760 K
Annual Net Income, $ -264,520 K
Last Quarter Sales, $ 30,660 K
Last Quarter Net Income, $ -56,010 K
60-Month Beta 0.24
% of Insider Shareholders 4.40%
% of Institutional Shareholders 29.47%
Float, K 138,577
% Float 95.60%
Short Volume Ratio 0.46

Growth:

1-Year Return -89.44%
3-Year Return -97.73%
5-Year Return -99.55%
5-Year Revenue Growth 185,850.00%
5-Year Earnings Growth 70.75%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.39 on 11/09/22
Next Earnings Date N/A
Earnings Per Share ttm -1.75
EPS Growth vs. Prev Qtr 9.30%
EPS Growth vs. Prev Year 30.36%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CLVS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -57.78%
Profit Margin % -177.82
Net Margin % N/A
Debt/Equity N/A
Price/Sales 0.34
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -2.89
Interest Coverage -6.77
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar